Operatore sanitario
Effettua il login per informazioni e servizi speciali

Aree Terapeutiche

AOP Orphan è focalizzata sulle malattie rare e di area critica. Il portafoglio prodotti si sviluppa nelle seguenti aree terapeutiche: emato-oncologia, cardiologia e pneumologia, neurologia e disturbi metabolici, terapia intensiva. L'obiettivo strategico di AOP Orphan è fornire costantemente nuove opzioni di trattamento per le malattie rare e di area critica.

EmatoOncologia

BESREMi®

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

Informazioni sul medicinale
Principio attivo
Ropeginterferon alfa-2b
Terapia intensiva

Empressin®

Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.

Informazioni sul medicinale
Principio attivo
Agripressin
Terapia intensiva

Esmocard® Lyo Esmolol Amomed

Esmolol hydrochloride is indicated for supraventricular tachycardia (except for pre-excitation syndromes) and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated for tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician’s judgement the rapid heart rate requires specific intervention.

Informazioni sul medicinale
Principio attivo
Esmolol
Terapia intensiva

Landiobloc

Informazioni sul medicinale
Principio attivo
Cardiologia e Pneumologia

TRESUVI®

Treatment of idiopathic or hereditary pulmonary arterial hypertension (PAH) for improving exercise capacity and alleviate disease symptoms in patients with New York Heart Association (NYHA) Functional Class III.

Informazioni sul medicinale
Principio attivo
Treprostinil
Cardiologia e Pneumologia

Trepulmix®

Trepulmix is indicated for the treatment of adult patients with WHO Functional Class (FC) III or IV and - inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or - persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.

Informazioni sul medicinale
Principio attivo
Trepulmix